News Briefing channel feed

Ex-Ed­i­tas CEO Ka­trine Bosley chairs Ar­rakis board; Car­du­ri­on touts Po­laris in­vest­ment

6 years ago

Ac­tivist in­vestor wages suit on On­coSec over re­cent deal; Breast can­cer ex­perts de­but biotech with $12M seed

6 years ago

Alk­er­mes sub­mits long await­ed NDA for schiz­o­phre­nia, bipo­lar drug; Is a uni­corn bub­ble drag­ging the IPO mar­ket?

6 years ago

Gene ther­a­py wins the in­side track at EMA; PPD files for IPO

6 years ago

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

6 years ago

Bio­Marin breaks out pos­i­tive PhII achon­dropla­sia da­ta; Ther­mo Fish­er opens 'cus­tomer so­lu­tion­s' fa­cil­i­ty in Chi­na

6 years ago

Seat­tle and Dai­ichi Sankyo at each oth­er's throats; UC Berke­ley, UCSF and the Uni­ver­si­ty of Wash­ing­ton launch Weill Neu­ro­hub

6 years ago

FDA’s Project Or­bis may ex­pand to Sin­ga­pore and Switzer­land

6 years ago

Am­gen ax­es 149 of its staff in Cam­bridge of­fice; Evotec, Mil­li­pore­Sig­ma en­ter re­search pact

6 years ago

Te­va spin­out rais­es $85M in IPO; No­var­tis beefs up gener­ics unit with $440M deal

6 years ago

Sarep­ta CEO dis­putes FDA re­venge nar­ra­tive; Take­da posts long-term da­ta on key Shire drug

6 years ago

Ob­sE­va shares crater af­ter PhI­II fail; Al­lena Phar­ma un­veils pos­i­tive late-stage da­ta

6 years ago

Re­gen­eron plans $1B stock buy­back; Mer­ck part­ner touts PhI­Ib re­sults for Keytru­da com­bo in pan­cre­at­ic can­cer

6 years ago

Steve Kaf­ka joins Sec­tion 32 as man­ag­ing part­ner; Take­da auc­tions off $660M drug port­fo­lio in bid to re­duce post-Shire M&A debt load

6 years ago

Tmu­ni­ty teams up with On­co­ra Med­ical; T3D re­ceives ad­di­tion­al fund­ing for Alzheimer's study

6 years ago

Ab­b­Vie show­cas­es pos­i­tive PhI­II da­ta for Rin­voq; RAPT prices on low end for IPO

6 years ago

San­i­fit touts pos­i­tive PhI­Ib da­ta; RE­GENXBIO li­cens­es Clear­side Bio­med­ical tech

6 years ago

Dupix­ent cleared for chron­ic rhi­nos­i­nusi­tis in EU; FDA grants RMAT sta­tus to CARs­gen's CAR-T

6 years ago

FDA ac­cepts Heron's painkiller re-sub­mis­sion; splits Blue­print Med­i­ci­nes' NDA for avapri­tinib

6 years ago

Proven­tion Bio's di­a­betes drug gains PRIME sta­tus; Avro­bio earns or­phan sta­tus

6 years ago

Am­gen com­mits to low-cost Repatha; AZTher­a­pies bags Smith Ther­a­peu­tic­s' CAR-Treg tech for neu­roin­flam­ma­tion

6 years ago
R&D

Neu­roRx se­cures $95M to fund PhI­II for NM­DA de­pres­sion drug; Trump re­vives sci­ence ad­vi­so­ry coun­cil

6 years ago

CD47 play­er Tril­li­um chops dis­cov­ery ef­forts and 40% of staff; Brii Bio inks deal to bring an­tibi­otics to Chi­na

6 years ago

Drug com­pa­nies reach $260M set­tle­ment just ahead of opi­oid tri­al; Oys­ter Point set terms for $85M IPO

6 years ago
First page Previous page 44454647484950 Next page Last page
A service from the Financial Times